Sign In
News Digest /
Ticker: GSK
Ticker: GSK
05:29am, Tuesday, Jun 09, 2026
GSK's stock dipped over 2% following its $10.6 billion acquisition of US biotech firm Nuvalent, centered on promising lung cancer treatments with FDA breakthrough designations. The deal carries a notable premium and plans to fuel revenue by 2027.
03:27am, Tuesday, May 12, 2026
Jiangsu Hengrui Pharmaceuticals' shares soared after announcing a global oncology and immunology development deal with Bristol-Myers Squibb worth up to $15.2 billion.
07:52am, Wednesday, Feb 04, 2026
Under new leadership, GSK forecasts more modest sales growth in 2026 as the company boosts its pipeline to offset impending patent losses on HIV drugs, aiming for robust gains by 2031.
07:16am, Wednesday, Jan 28, 2026
FTSE 100 dips 0.4% as pharma and bank stocks retreat; FTSE 250 gains ground. Gold prices rally, energy shares up on oil boost, luxury brands stumble on weak earnings reports.
08:48am, Monday, Jan 05, 2026
China's health regulator approves GSK's Nucala (mepolizumab) as an add-on monthly treatment for adults with chronic obstructive pulmonary disease marked by high eosinophil levels, aiming to curb flare-ups and hospital visits.
04:59am, Friday, Dec 12, 2025
GSK's RSV vaccine Arexvy cleared by CHMP to be used in all adults 18+, expanding from prior age limits. European Commission decision expected in Feb 2026.
07:44am, Thursday, Nov 20, 2025
Moderna lands a $1.5 billion loan from Ares Management and forecasts a 10% revenue lift next year despite recent pipeline cuts. The biotech readies new vaccine launches to reclaim market share.
07:31am, Monday, Oct 06, 2025
FDA asks GSK to refile branded leucovorin for cerebral folate deficiency, fast‑tracking a label change that could boost prescriptions and generic sales (Hikma). Traders watch insurer coverage and a precedent for quicker repurposing.
03:49am, Wednesday, Sep 17, 2025
GSK pledges $30B and Eli Lilly $5B for U.S. manufacturing to expand biologics capacity and hedge against potential import levies-part of a $350B industry onshoring push that could reshape margins, supply chains and jobs.
08:43am, Wednesday, Jul 16, 2025
GSK faces FDA scrutiny over safety concerns with its new blood cancer drug, including risks of eye damage when combined with other treatments. This raises approval hurdles and puts pressure on GSK shares amid ongoing regulatory challenges.
02:30am, Monday, Jul 14, 2025
GSK is seeking FDA approval to expand its RSV vaccine, Arexvy, to high-risk adults under 50. This strategic move could boost market share and attract investor interest. Traders should monitor the developments closely as approval may impact stock performance.
07:22am, Monday, Jan 13, 2025
British pharma giant GSK plans to acquire Boston-based IDRx for up to $1.15 billion, enhancing its gastrointestinal cancer portfolio. This strategic move aims to innovate cancer therapies and restore investor confidence amidst recent challenges.
04:10am, Thursday, Oct 10, 2024
GSK plc's shares surged 6.6% to £1,554.23 after announcing a $2.2 billion settlement for 80,000 Zantac lawsuits in the U.S. The agreement resolves 93% of pending cases, potentially stabilizing the company’s future for investors amid litigation uncertainties.
04:55am, Wednesday, Jul 03, 2024
GSK (LSE: GSK) acquired CureVac's (NASDAQ: CVAC) share in joint flu and COVID-19 vaccine projects, enhancing its mRNA tech expertise. CureVac's stock surged 24%, extending its financial runway to 2028 but will cut 30% of its workforce to focus on cancer therapies.
07:49am, Thursday, Jun 27, 2024
U.S. stock markets opened lower on Thursday as tech shares dragged indices down. Micron (MU) dropped 6% with a poor financial forecast, Levi Strauss (LEVI) plummeted 16% due to weak Dockers brand revenue, and Walgreens (WBA) fell 4.8% after slashing its fiscal 2024 guidance. International Paper (...
04:37am, Thursday, Jun 27, 2024
GSK's stock (NYSE: GSK) plunged over 6% after the US CDC restricted RSV vaccine use, recommending it only for high-risk individuals aged 60-74. The change impacts GSK's Arexvy vaccine, crucial for revenue amidst looming patent expirations. Analyst forecasts may be revised downwards.